Work

Antibody-Based Biopharmaceuticals: A Brief Overview of Monoclonal Antibodies and Antibody–Drug Conjugates

Year: 2026
Type: article
Abstract: Biopharmaceuticals have transformed modern medicine by enabling highly specific and targeted therapeutic interventions for a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and genetic conditions. Advances in recombinant DNA technology, protein engineering, and biotechnology have expanded the development of complex biological products with improved efficacy and safety profiles compared with many conventional small-molecule drugs. Among these products, monoclonal antibodies (mAbs) and antibody–drug conjugates (ADCs) have emerged as two of the most successful and rapidly evolving therapeutic modalities. Monoclonal antibodies provide selective target recognition and have become integral components of treatment strategies across multiple disease areas, whereas ADCs combine the specificity of antibodies with the potent cytotoxic activity of small-molecule payloads to enhance therapeutic precision. This review provides a focused overview of biopharmaceuticals, with particular emphasis on the structural characteristics, mechanisms of action, clinical applications, and approved products of mAbs and ADCs. In addition, key challenges associated with their development, characterization, and quality control are briefly discussed. Collectively, these therapeutics continue to play a pivotal role in modern medicine and represent an important direction for future biopharmaceutical innovation.
Source: DergiPark
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W7166497520
FWCI:
Cites: 35
Cited by:
Related to: 10